endo.comHome | Endo

endo.com Profile

endo.com is a domain that was created on 1998-09-04,making it 26 years ago. It has several subdomains, such as codeofconduct.endo.com , among others.

Discover endo.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site

endo.com Information

HomePage size: 130.666 KB
Page Load Time: 0.086917 Seconds
Website IP Address: 52.162.107.10

endo.com Similar Website

StoreFront – Edge Endo LLC Online Store
store.edgeendo.com
American Association of Endodontists (AAE), AAE Endo Careers|Find Your Career Here
endocareers.aae.org

endo.com PopUrls

Home | Endo
https://www.endo.com/
Endo Pharmaceuticals Jobs
https://jobs.endo.com/
Investors | Endo - Overview
https://investor.endo.com/
Endo Pharmaceuticals | Home
https://www.endo.com/endopharma
Endo Pharmaceutical | Remote Support
https://support.endo.com/
About Us
https://www.endo.com/about-us
Benefits
https://www.endo.com/careers/benefits
Site Map
https://www.endo.com/home/sitemap
Search
https://www.endo.com/home/search
Careers | Endo
https://www.endo.com/careers
Focus Areas | Endo
https://www.endo.com/products-and-capabilities/focus-areas/
Endo, Inc. Completes Acquisition of Endo International plc's Assets
https://investor.endo.com/2024-04-23-Endo,-Inc-Completes-Acquisition-of-Endo-International-plcs-Assets
Endo Reports Fourth-quarter and Full-year 2021 Financial Results
https://investor.endo.com/news-releases/news-release-details/endo-reports-fourth-quarter-and-full-year-2021-financial-results
Endo Reports Second-quarter 2022 Financial Results
https://investor.endo.com/news-releases/news-release-details/endo-reports-second-quarter-2022-financial-results
History | Endo
https://www.endo.com/company/history/

endo.com DNS

A endo.com. 300 IN A 52.162.107.10
MX endo.com. 8400 IN MX 20 us-smtp-inbound-2.mimecast.com.
NS endo.com. 14400 IN NS dns1.cscdns.net.
TXT endo.com. 14400 IN TXT FiGIgJK7lEWi7z5/eE0gf5TjObpVkLOXe3WYRxay0nI2/ECWOk/yahK8rpyUHd1Ol/M72ZARy3Aj3U3ZbTjgaQ==
SOA endo.com. 14400 IN SOA dns1.cscdns.net. hostmaster.cscdns.net. 2016062535 28800 7200 604800 14400

endo.com Httpheader

Content-Type: text/html; charset=utf-8
Date: Tue, 14 May 2024 13:33:08 GMT
Access-Control-Allow-Origin: https://www.endo.com
Cache-Control: no-cache
Set-Cookie: TiPMix=89.2125780747467; path=/; HttpOnly; Domain=endo.com; Max-Age=3600; Secure; SameSite=None, x-ms-routing-name=self; path=/; HttpOnly; Domain=endo.com; Max-Age=3600; Secure; SameSite=None, ARRAffinity=ddc72a5c19a48c1cc7a2c32669d26e4b5a0ca27b4c07ca8626aaa5c0822c8e3d;Path=/;HttpOnly;Secure;Domain=endo.com, ARRAffinitySameSite=ddc72a5c19a48c1cc7a2c32669d26e4b5a0ca27b4c07ca8626aaa5c0822c8e3d;Path=/;HttpOnly;SameSite=None;Secure;Domain=endo.com
Transfer-Encoding: chunked
Content-Security-Policy: "default-src self; font-src self *.typekit.net; frame-src self https://www.google.com; img-src self data: *.cookielaw.org *.googletagmanger.com;connect-src self *.azure.com *.cookielaw.org *.google-analytics.com *.azure.com *.onetrust.com; script-src self unsafe-hashes https://www.google.com https://www.gstatic.com https://www.googletagmanager.com *.azure.com *.cookielaw.org code.jquery.com cdnjs.cloudflare.com/ajax/libs/mustache.js/3.0.1/mustache.min.js sha256-IgMQOOOedQeMPBl7lSreMVPmJvU62bc6l8HcsGXnbWc= sha256-vnIteLi/4D5Rd8MqyH0dOUaiEq9LyTAmioGbHFgSukY= sha256-7Y0925E4fL/kVY0FPsg7h/d4iMZ0UB73UNV0TI7z5k4= sha256-X0tmXAhlbW8eAyknsixrU1qMnovSuKpkTbYAkf0zKok= sha256-nM+Ab7qquSLfTm0j5RK4XBaXyha829P3y3++/Fu5RiI= sha256-NPxyNhRU6zRaWY3u9nF03GypfQE6FgHW5zQRRfJgZJE= sha256-FPxRC1fk7FlrTxcDo1dGoXOhXE72z5GnihW9A2KCLHI=; style-src self *.typekit.net sha256-SOhOSQb9PBBMF2YZ0/2fig8fzjEoiGIGwdoBB5gx5QA=; style-src-attr unsafe-hashes sha256-8uIBRn2k0TYjS8tgVdxW/UG+TNG4YQNmg/k2jG9Ob9w= sha256-BhMTvCZP93987mIWerrkiUoDYrtXh1rdiuEqH7GXKqM= sha256-LEQrqfjnGIHOubuamwWbPEFODKNURL4g13CHZiysWCI= sha256-pc7tKkoLF1QChIXajelvln1qKYwLdW9mR+I/DNUKQJ8= sha256-1MfM5qMsK+UHYMQSHLRC9AkIsCAXq2OlCZ4C9cNllYA= sha256-247LC4mjZA3ATkuKMT9B8iol8RckkkDq6SOKAaWaeUA= sha256-n5R46MqtNeMd6W3/yYDvG8LG99RnuFRGP3SeJaUdaM0= sha256-Jf1Xk51sP3O8F176ZVXTWrUBiIBXUjwshILtM6hXtC4= sha256-VyYxxf095er1oB6bp9EAryRZNTZbvjB+pd++a7+bze8= sha256-X2oYoxjRx2sYxBzdWRmyZZcPD2hs+pSbM1Pjl6Czlv8= sha256-SOhOSQb9PBBMF2YZ0/2fig8fzjEoiGIGwdoBB5gx5QA= sha256-qHVxd1YV4srh9ALSgrADQrtdGzeqlMb3CGjIDAhRWsg= sha256-YTEza4CA2qPCNGLfB6mKa5FjY8kjkO/K7nQxeJxVd9E= sha256-JN34oVk9jCYhnPdJff1gLu5SCQYQ7BbolG6xVY5GAus= sha256-J91uMkQnRXRkd/VjWs4OVJTm4fPWEzZWUZ0Y3mIVnn0= sha256-+17AcPK/e5AtiK52Z2vnx3uG3BMzyzRr4Qv5UQsEbDU= sha256-+17AcPK/e5AtiK52Z2vnx3uG3BMzyzRr4Qv5UQsEbDU= sha256-+DlHyF9DqqE4+WJUq3vwc5l6CPTGcCBBTALPGo2CEaQ= sha256-cglPMe+s6vDUD3l8Z6lHMLTMx2E+bKxXw/vjNkJd91o= sha256-JNaVGttgomZgMeQFUdZctzcaJFPadqLqk03Dv1gWuE8= sha256-JNaVGttgomZgMeQFUdZctzcaJFPadqLqk03Dv1gWuE8= sha256-7Xkko/VqYAUdCUwh6tb0036Ee5LULxnkvesQxtjvc6Y= sha256-2WCl13H+4ddTuP+6bCT7Bwt6+gQrYjuwCO/5g8zEoVM= sha256-gaPYuJayZW+h+jDDIFTkaJM5onYErQxMwyns+JIVt0U= sha256-RgsX94xmeu/ePwfQn8XONo3cXEHtOpp2KYdFho+b9Ic= sha256-aqNNdDLnnrDOnTNdkJpYlAxKVJtLt9CtFLklmInuUAE= sha256-S7D/DUF26c6v2yrWCxfujigmrrK2cFVcy06Zr/A/J38= sha256-kDJtnL/rdEoIoCh/ftMoowdUt74Boy/3GQDCun4RsMc= sha256-w1PChBcHfesUCaMQgdb+5jtKvDKesFoSVOIr4YTyL/s= sha256-+EU1mGB0xCGABqaUaOiKIHRSHkitxWbWIf9VOFIASmU= sha256-ceTcOH8kBt+kVA5R+j3LlUxnft0f8intIjjpBTTvX3A= sha256-LEhDc9AZazH2D0oXBscMe9LrgWRDnO7yCJgJzT/EsH8= sha256-MIwfcbq7MKaol4QWewSYK02jjcciXLASdtMz7YYq0Q8= sha256-pIW7quII+HRWnHOLd/8JXFu8Ti/gYl0bsc9t2KNNWXQ= sha256-uDFAT3aQ+rBcqGTPiCxp+N4k+JaeM+nsgINLyCDOpiM= sha256-f8HkaZCZ0EO8c2L1aX93F91VPVA+pqcWBfv18HB0CrQ=; block-all-mixed-content;", X-Content-Type-Options: nosniff
X-Frame-Options: SAMEORIGIN
X-XSS-Protection: 1; mode=block

endo.com Meta Info

charset="utf-8"/
content="width=device-width, initial-scale=1" name="viewport"/
content="" name="description"/
content="Home" property="og:title"/
content="website" property="og:type"/
content="https://endo.com/" property="og:url"/
content="https://endo.com/media/q2zlwrsp/hero-home-1.webp" property="og:image"/
content="" property="og:description"/
content="#faf9f8" name="theme-color"/

endo.com Ip Information

Ip Country: United States
City Name: Chicago
Latitude: 41.8874
Longitude: -87.6318

endo.com Html To Plain Text

Company Purpose Leadership History Policies & Statements Contact & Locations Products & Capabilities Focus Areas Products Manufacturing Suppliers Research & Development R&D Approach Pipeline Clinical Research Grants Newsroom Media Stories Responsibility Ethics & Compliance Team & Culture Customers & Patients Environment Partnerships Progress & Reports Investors Careers Inspired for life We’re boldly transforming insights into life-enhancing therapies. See the Video Ready for Tomorrow, Inspired for Life Read the Story How Ready-to-Use Medications May Help Reduce Hospital Complexity Read the Story 2024 Living Our Values Award Winners Read the Story Supplier Diversity: Powering Success and Opportunities Read the Story Our Company Life-Enhancing Therapies Our mission drives us: through focused insights and execution, we develop and deliver life-enhancing therapies. Our team members collaborate to bring forward pharmaceutical solutions that make a real difference for customers and patients. About Endo Expanding Together Endo’s century-long manufacturing legacy encompasses life-saving products and contributions to science and technology. The new 90,000-square-foot facility in Rochester, Michigan builds on this history and supports future innovations in medicine. Read the Story Products & Capabilities Learn More Specialty Medicines We empower patients and build trust with urologists, orthopedic surgeons, pediatric endocrinologists, and other specialists. This relentless focus delivers meaningful therapies and seamless experiences that help enable successful outcomes in both U.S. and Canada. Learn More Sterile Injectables We partner with hospitals and healthcare systems to reduce complexity through life-enhancing solutions, including sterile injectable and ready-to-use products. Together, we innovate to add value where it matters—from manufacturing to treatment—so healthcare providers can focus on patient care. Learn More Generics We are dedicated to delivering high-quality generic products in a variety of forms and dosages through retail, mail-order, and other patient-facing pharmacy networks. We achieve this through excellence in research and development, manufacturing, and commercialization. Research & Development Patient Focus We strive to deliver products that address unmet patient needs. Our efforts focus on specialty medical therapeutics, sterile injectables, and high-value generic medicines. We’re discovering tomorrow’s treatments through our forward-focused research and development, executing with a quality mindset. Learn More Why clinical trial sites are among Endo’s most important partners. Healthcare providers at practices around the world share their time and expertise as they participate in patient trials, lead patients on their journeys, and help advance medical innovations. Read the Story By the Numbers Measuring Our Global Impact 3,000 Global Team Members 2.6 M Prescriptions Dispensed Each Month 180 Products Available to Patients and Providers 60 Products in Pipeline 1 M Square Feet of Global Manufacturing 220 Conditions Treated Through Our Medicines Updated April 23, 2024 Collaborative Health Efforts Patient and Community-Driven Care At Endo, our dedication extends beyond developing quality products. With a rich history, we empower individuals and communities alike, fostering better health outcomes and a brighter future for all. We are driven to improve lives—from patients seeking effective treatments, to healthcare providers striving to deliver exceptional care, to investors relying on our forward progress and aspirational goals for the future. Reaching Patients in Need in India In remote areas, access to healthcare is often limited. Our Mobile Health Unit bridges this gap, providing essential services to thousands in Chennai and Indore, India. Read the Story Download the mp4 video. Our Responsibility Committed to the Adoption of More Sustainable Practices We strive to help everyone we serve live their best life, and that vision calls on us to be a force for good in everything we do. Integrity We aim to do the right thing, always. That means operating with unwavering ethical standards, taking accountability, and embracing a quality mindset. Our Business Practices Culture of Excellence Our commitment to quality and safety drives our work, from the initial stages of research and development to the delivery of our products to those who need them. Our Customers Sustainability We operate our business in a responsible manner that seeks to minimize environmental impact. Our World News & Announcements Press Releases May 7, 2024 Endo Announces New Peyronie’s Disease Data Presented at the American Urological Association Annual Meeting Read the Press Release May 6, 2024 Endo Launches Enhanced TruDelivery® Ready-to-Use Product Line and Platform Read the Press Release April 23, 2024 Endo, Inc. Completes Acquisition of Endo International plc’s Assets Read the Press Release April 22, 2024 Par Pharmaceutical Issues Voluntary Nationwide Recall of Seven Lots of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution Read the Press Release April 11, 2024 Endo, Inc. Announces Pricing of $1.5 billion of Senior Secured Term Loan as Part of Endo’s $2.5 billion Exit Financing Read the Press Release April 11, 2024 Endo, Inc. Announces Pricing of $1.0 billion of Senior Secured Notes Read the Press Release April 8, 2024 Endo, Inc. Announces Proposed Private Offering of Senior Secured Notes Read the Press Release See All Press Releases Our Team Defining the Future of Healthcare Our global team of nearly 3,000 dedicated professionals are united by a shared vision—to help everyone we serve live their best life. We strive to make a lasting impact through our unwavering commitment to excellence. We’re seeking team members with a passion for pushing boundaries and shaping the future. Explore our career opportunities and find out why we’re #EndoProud . Join Our Team Meet the Team Our distinct stories and values shape our journey and make us #EndoProud. Discover the Endo difference through the eyes of those who know it best. Hear from Our Team Members Sign up for news alerts for everything Endo. © 2024 Endo, Inc. or one of its affiliates Privacy/Legal Code of Conduct Corporate Compliance Site Map Cookies Settings Company Purpose Leadership History Policies & Statements Contact & Locations Products & Capabilities Focus Areas Products Manufacturing Suppliers Research & Development R&D Approach Pipeline Clinical Research Grants Contact Us 1-800-462-ENDO (3636) Contact Us Stay in Touch Sign Up for News AlertsNewsroom Media Stories Responsibility Ethics & Compliance Team & Culture Customers & Patients Environment Partnerships Progress & Reports Information Investors Careers Employee BenefitsYour browser does not support the video...

endo.com Whois

Domain Name: ENDO.COM Registry Domain ID: 1912875_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.corporatedomains.com Registrar URL: http://cscdbs.com Updated Date: 2023-08-29T06:03:35Z Creation Date: 1998-09-04T04:00:00Z Registry Expiry Date: 2024-09-03T04:00:00Z Registrar: CSC Corporate Domains, Inc. Registrar IANA ID: 299 Registrar Abuse Contact Email: domainabuse@cscglobal.com Registrar Abuse Contact Phone: 8887802723 Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Name Server: DNS1.CSCDNS.NET Name Server: DNS2.CSCDNS.NET DNSSEC: unsigned >>> Last update of whois database: 2024-05-17T20:12:09Z <<<